Clinically, the high prevalence of GCGR expression in pNET tissues and its inverse correlation with tumour grade, alongside the reduced GLP-1R expression, point to disrupted insulin–glucagon signalling in tumour progression. This evidence concerns the gene GLP1R and neoplasm.